ClinicalTrials.gg
CompletedNCT00704132Updated May 12, 2017Results posted

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

A Phase 1 interventional study of Comparator: sitagliptin phosphate and Comparator: placebo (unspecified) in Type 2 Diabetes Mellitus (T2DM), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2007, registered Jun 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
127th of 197
57 · median 102
Started
2007
with 16 others
Phase 1
23 of 198
none open now
Registered
48th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 127th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 23 in phase 1, and was the 48th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has type 2 diabetes mellitus
  • Males
  • Females who are highly unlikely to become pregnant
  • Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of type 1 diabetes mellitus or history of ketoacidosis
  • Participant required insulin therapy within the prior 8 weeks
  • Participant is on or has been taking TZDs such as Actos® (pioglitazone) or Avandia® (rosiglitazone) within the prior 12 weeks of the screening visit
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    sitagliptin

    Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.

    Drug: Comparator: sitagliptin phosphate

  • Placebo comparator
    Placebo

    Participants randomized to this arm will be administered matching placebo, daily for six weeks.

    Drug: Comparator: placebo (unspecified)

Interventions

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin tablet 100 mg, administered once daily before the morning meal.

  • DrugComparator: placebo (unspecified)

    Matching placebo tablet, administered once daily before the morning meal.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6

    Participants underwent the 5-hour meal test prior to randomization (baseline) and was repeated at the conclusion of the 6-week double-blind study period. The change from baseline in Glucose 5-Hour Incremental AUC at Week 6 is computed as the difference between the Week 6 measurement and the baseline measurement.

    Time frame: Baseline and Week 6

07

Results

Posted May 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started2624
Completed2522
Not completed12
Withdrew: Clinical adverse experience10
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline in Glucose 5-Hour Incremental AUC at Week 6

Participants underwent the 5-hour meal test prior to randomization (baseline) and was repeated at the conclusion of the 6-week double-blind study period. The change from baseline in Glucose 5-Hour Incremental AUC at Week 6 is computed as the difference between the Week 6 measurement and the baseline measurement.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · mg*hr/dL
Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6
mg*hr/dLSitagliptinPlacebo
Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6-83.9 ± 87.727.0 ± 84.3
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <0.001 · Difference in least-squares mean: -111.0 · 95% CI -158.0 to -63.9Sitagliptin minus Placebo

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—1/26 (3.8%)0/26 (0%)
Placebo—0/24 (0%)0/24 (0%)
Most frequent serious events
Most frequent serious events
EventSitagliptinPlacebo
Vertigo positionalEar and labyrinth disorders1/260/24

Baseline characteristics

Age, Customized
Age, Customized(participants)SitagliptinPlaceboTotal
Number262450
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female7815
Male191635
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8. PubMed 22685234 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Apr 2010, 38 months.

Results were first posted in May 2011, 1 year after primary completion.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 38 months is above that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2008
First posted
Jun 24, 2008
StartActual
Feb 14, 2007
Primary completionActual
Apr 28, 2010
CompletionActual
Apr 28, 2010
Results first posted
May 16, 2011
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00704132
Responsible party
Sponsor
First posted
Jun 24, 2008
Start date
Feb 14, 2007
Primary completion
Apr 28, 2010
Completion
Apr 28, 2010
Results posted
May 16, 2011
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion